Considerations for platform AAV affinity capture

From discovery to the clinic, as the quest to produce new, high-quality AAV molecules intensifies, an efficient and scalable platform purification process for many AAV serotypes is advantageous for both drug developers and CDMOs. In this poster, the considerations for evaluating a platform affinity capture step involving the industry leading POROSTM CaptureSelectTM AAV affinity resin for the purification of AAV vectors are explored.

Please enter your email to access content Read now